CLOs on the Move

Macrocure

www.macrocure.com

 
Macrocure Ltd. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Our novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body`s own wound healing and regenerative components directly into the wound itself.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.macrocure.com
  • Radnor Financial Center, Suite F200 150 North Radnor Road
    Radnor, PA USA 19087
  • Phone: 201.620.6640

Executives

Name Title Contact Details

Similar Companies

Shiel Medical Laboratories

Shiel offers a comprehensive menu of test and diagnostic options through participating physicians and health care providers, and through our ever expanding Patient Service Center Network. Our full-service in-house pathology department performs GYN (Pap

Intendis

Intendis is a Pine Brook, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aurobindo Pharma USA

Aurobindo USA is committed to delivering a broad portfolio of quality, affordable generic pharmaceuticals to pharmacists and patients. Since its first US ANDA approval in 2004, Aurobindo has expanded its portfolio to include more than 125 product families and 450 individual product packages, representing a wide range of therapeutic categories. Aurobindo has been recognized as the fastest growing pharmaceutical company in 2012,* and in early 2013, thanks to the ongoing support of our customers, became one of the top 10 pharmaceutical companies, brand or generic, in terms of total prescriptions dispensed.**

ProTom International

Protoms Radiance 330 Proton Therapy System is compact, customizable, and has the industrys fastest return on investment.

Precision Medicine Group

We founded Precision Medicine Group in 2012 because we believed there was a transformational opportunity to improve the process of bringing new drugs to market. It involves utilizing technology, data, and human expertise. It is a big challenge that requires diverse talents. Our model involves both nurturing and investing organically and acquiring capabilities that we do not have but critically need. Our core executive team is anchored to this model, building life science services that address fundamental changes in healthcare that are necessary for health and outcomes improvement.